Victory Capital Management
SNDX icon

Victory Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Victory Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$895K Buy
38,331
+28,624
+295% +$622K ﹤0.01% 1884
2025
Q4 		$204K Buy
+9,707
New +$169K ﹤0.01% 2202
2025
Q2 		– Sell
-10,148
Closed -$125K – 2551
2025
Q1 		$125K Buy
10,148
+119
+1% +$1.68K ﹤0.01% 2284
2024
Q4 		$133K Sell
10,029
-56
-0.6% -$958 ﹤0.01% 2302
2024
Q3 		$194K Sell
10,085
-255
-2% -$5.27K ﹤0.01% 2232
2024
Q2 		$212K Sell
10,340
-265
-2% -$5.55K ﹤0.01% 2188
2024
Q1 		$252K Buy
+10,605
New +$237K ﹤0.01% 2159
2023
Q2 		– Sell
-16,033
Closed -$339K – 2594
2023
Q1 		$339K Sell
16,033
-5,871
-27% -$146K ﹤0.01% 2113
2022
Q4 		$557K Sell
21,904
-6,160
-22% -$144K ﹤0.01% 1976
2022
Q3 		$675K Buy
28,064
+6,656
+31% +$149K ﹤0.01% 1912
2022
Q2 		$412K Buy
21,408
+1,582
+8% +$26.4K ﹤0.01% 2136
2022
Q1 		$332K Buy
+19,826
New +$334K ﹤0.01% 2262
2020
Q2 		– Sell
-8,572
Closed -$94K – 3184
2020
Q1 		$94K Buy
+8,572
New +$80.4K ﹤0.01% 2553
2019
Q4 		– Sell
-4,440
Closed -$33K – 3195
2019
Q3 		$33K Buy
+4,440
New +$40.4K ﹤0.01% 2867

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Victory Capital Management's SNDX Position: Q1 2026 in Review

Victory Capital Management increased its Syndax Pharmaceuticals (SNDX) stake by 295% in Q1 2026, buying an estimated $622K and bringing the position to 38,331 shares worth $895K. The position accounts for ﹤0.01% of the portfolio, ranked #1884.

Victory Capital Management first reported a position in SNDX in Q3 2019 and has held it in 14 quarters since. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Victory Capital Management held 38,331 shares of Syndax Pharmaceuticals worth $895K as of Q1 2026.
  • Victory Capital Management bought 28,624 Syndax Pharmaceuticals shares in Q1 2026, an estimated $622K.
  • Syndax Pharmaceuticals made up ﹤0.01% of Victory Capital Management's portfolio in Q1 2026, its #1884 holding.
  • Victory Capital Management first reported a position in Syndax Pharmaceuticals in Q3 2019 and has held it in 14 quarters since.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.